14 results about "Anticarcinogen" patented technology

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

An anticancer agent is provided comprising, as active ingredients, NK cells and a fusion protein comprising an IL-2 protein and a CD80 protein. In one specific formulation, a fusion protein comprising a CD80 fragment, an immunoglobulin Fc region, and an IL-2 variant can activate immune cells such as natural killer cells. Furthermore, since the pharmaceutical composition can effectively inhibit cancer, when co-administered with natural killer cells, it increases immune activity in the body, making it effective for cancer treatment and thus highly applicable to industry.

The present disclosure provides polypeptide constructs that, when exposed to sufficient levels of ATP, cause them to assemble into dimers or higher order complexes (e.g., trimers, tetramers, etc.), thereby acting as immune cell function agonists. The constructs can also be conjugated to one or more therapeutic, chemotherapeutic, or labeling agents. The complexes of the constructs are capable of stimulating immune cells (e.g., cytotoxic CD8+ T cells and / or NK cells) that function to promote an anti-tumor immune response, and delivering the conjugated agent to the tumor microenvironment. The constructs can be used as anti-cancer / therapeutic agents for the treatment of solid tumors with elevated ATP levels.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, containing a mTOR-signaling inhibitor as an active ingredient. The composition of the present invention exhibits the efficacy of inhibiting the growth of cancer cells and killing cancer cells, and thus can be used as an anticancer agent.

The present disclosure relates to heterocyclic compounds, pharmaceutical compositions comprising said compounds and a method of treating cancer comprising administering the compounds, or compositions thereof to a subject in need thereof. Specifically, the present disclosure provides heterocyclic compounds useful as anti-cancer agents, pharmaceutical compositions comprising said compounds and a method of treating SULT1 positive cancer comprising administering the compounds, or compositions thereof to a subject in need thereof.

Provided are a pharmaceutical combination and a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form thereof and at least one other anticancer agent, and use thereof in the preparation of a medicine for treating a malignant tumor disease. The other anticancer agent is a CDK inhibitor or a pharmaceutically acceptable salt thereof (such as palbociclib), lenvatinib or a pharmaceutically acceptable salt thereof, sorafenib or a pharmaceutically acceptable salt thereof, or any combination of the above.

The present invention provides a pharmaceutical composition for cancer treatment, comprising a fusion protein containing IL-2 protein and CD80 protein and an anticancer agent as active ingredients. One embodiment of the present invention, a fusion protein containing a CD80 fragment, immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells and simultaneously suppress the immune cell-regulating activity of regulatory T cells. Furthermore, when administered in combination with an anticancer agent, the fusion protein can effectively suppress cancer. A pharmaceutical composition comprising a fusion protein containing IL-2 protein and CD80 protein and an anticancer agent as active ingredients increases immune activity in the body, making it effective for treating not only cancer but also infectious diseases, making it highly applicable industrially.

Provided is a cancer-associated fibroblast inhibitor, particularly a cancer-associated fibroblast inhibitor capable of enhancing the anticancer effect of an anticancer agent. A cancer-associated fibroblast inhibitor containing a PDGFR inhibitor.

The present invention relates to: an immuno-oncology composition comprising an anti-MUC1 antibody or an antigen-binding fragment thereof that specifically binds to a polypeptide comprising the C-terminal extracellular domain of Mucin 1 (MUC1); and a use for inducing an immuno-oncology response in a subject by using same. The anti-MUC1 antibody or antigen-binding fragment thereof that specifically binds to a polypeptide comprising the C-terminal extracellular domain of MUC1 according to the present invention does not exhibit direct cytotoxicity to cancer cells, induces an increase in the activity of immune cells, and exhibits antibody-dependent cellular cytotoxicity (ADCC) by inhibiting immune evasion of cancer. Therefore, the anti-MUC1 antibody or antigen-binding fragment thereof can be used as various types of immuno-oncology agents, immuno-oncology adjuvants, or combination therapeutic agents for inducing an immune response in a subject and enhancing an anticancer effect.

The present invention provides a medicine for treating or preventing cancer, the medicine comprising a first active ingredient used together with a second active ingredient, the first active ingredient being a compound represented by formula (1) or a salt thereof, or a solvate thereof, the second active ingredient being an anticancer agent.

This article provides a method for treating lymphoma using anticancer agents and anticancer therapies, wherein the first anticancer agent is represented by formula (I) or a pharmaceutically acceptable salt thereof.

Provided are a glypican-3 (GPC3)-specific modified aptamer, and prevention or treatment of hepatoma using the same. The glypican-3-specific modified aptamer of the present invention specifically binds to glypican-3 to be internalized into hepatoma cells, and exhibits anticancer activity through an anticancer agent bound to the aptamer, and therefore, has a selective anticancer effect only for GPC3-expressing hepatoma cells without affecting normal hepatocytes.

The present invention provides a compound having the structure of formula (I) and that can be used as an SHP2 inhibitor, a pharmaceutical composition containing the compound, a method for preparing the compound, and the use of the compound in the treatment of cancer. TIFF2026523001000265.tif50130